Sugi Predict

Sugi Predict / Compounds / SCHEMBL503744

SCHEMBL503744

SCHEMBL503744

C[Si](C)(C)C#Cc1cnc2[nH]ncc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 6/20 0.39
▸ MAP3K20 Q9NYL2 1/20 0.36
▸ PIK3C3 Q8NEB9 3/20 0.34
▸ ABL1 P00519 4/20 0.32
▸ PDPK1 O15530 1/20 0.32
▸ CHEK1 O14757 1/20 0.31
▸ AURKA O14965 1/20 0.31
▸ LRRK2 Q5S007 2/20 0.31
▸ RET P07949 1/20 0.31
▸ PI4KA P42356 1/20 0.31
▸ XDH P47989 1/20 0.31
▸ PI4K2B Q8TCG2 1/20 0.31
▸ PI4K2A Q9BTU6 1/20 0.31
▸ PI4KB Q9UBF8 1/20 0.31
▸ FGFR1 P11362 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ PDGFRA P16234 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25952937 0.78 BRAF (0.40) BRAFMAP3K20PIK3C3ABL1PDPK1
SCHEMBL29543783 0.77 RIPK1 (0.47) BRAFMAP3K20ABL1PDPK1CHEK1
SCHEMBL297592 0.77 RIPK1 (0.47) BRAFMAP3K20ABL1PDPK1CHEK1
SCHEMBL3643549 0.75 NOS1 (0.47) —
SCHEMBL1586122 0.75 CYP2C19 (0.42) BRAFMAP3K20PIK3C3ABL1PDPK1
SCHEMBL5123072 0.74 KDM4E (0.41) BRAFPIK3C3LRRK2RETPI4KA
SCHEMBL30726289 0.74 KDM4E (0.41) BRAFPIK3C3LRRK2RETPI4KA
SCHEMBL502852 0.74 PARP1 (0.37) BRAFMAP3K20PIK3C3ABL1PDPK1
SCHEMBL18762343 0.73 PDE3B (0.37) —
SCHEMBL28503736 0.73 CCR1 (0.50) PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119661503-A 4-Ethynyl pyridine derivatives as GCN2 inhibitors IP2IPO创新有限公司 2025-03-21 — — CN disclosed
CN-116113629-B 4-Ethynyl pyridine derivatives as GCN2 inhibitors IP2IPO创新有限公司 2024-12-31 — — CN disclosed
US-20240150345-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF PHARMARON UK LTD. (GB) 2024-05-09 — — US disclosed
US-11945799-B2 4-ethynylpyridine derivatives useful as GCN2 inhibitors IP2IPO INNOVATIONS LIMITED (GB) 2024-04-02 — — US disclosed
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 — — US disclosed
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 — — US disclosed
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 — — US disclosed
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-10 — — US disclosed
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-10 — — US disclosed
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-10 — — US disclosed
EP-2421846-A1 5-ALKYNYL-PYRIDINES Boehringer Ingelheim International GmbH (DE) 2012-02-29 — — EP disclosed
US-20120028952-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-02 — — US disclosed
US-20120028952-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-02 — — US disclosed
US-20120028958-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-02 — — US disclosed
US-20120028958-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-02 — — US disclosed
US-20110281838-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-17 — — US disclosed
US-20110281838-A1 5-ALKYNYL-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-17 — — US disclosed
US-20110098275-A1 5-ALKYNYL-PYRIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-28 — — US disclosed
US-20110098275-A1 5-ALKYNYL-PYRIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-28 — — US disclosed
WO-2010122069-A1 5-ALKYNYL-PYRIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B BRAF 2826/4885MAP3K20 1276/4885PIK3C3 2472/4885
US-20120028958-A1 5-ALKYNYL-PYRIMIDINES MKI67, CCNA1, CCNT1 BRAF 552/4885MAP3K20 1013/4885PIK3C3 3155/4885
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B BRAF 2826/4885MAP3K20 1276/4885PIK3C3 2472/4885
US-20110281838-A1 5-ALKYNYL-PYRIMIDINES MKI67, CCNA1, CCNT1 BRAF 677/4885MAP3K20 1241/4885PIK3C3 3615/4885
US-20240150345-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF EIF2AK4, GCN1, CLN6 BRAF 2092/4885MAP3K20 942/4885PIK3C3 4585/4885
US-20120028952-A1 5-ALKYNYL-PYRIMIDINES MKI67, CCNA1, CCNT1 BRAF 557/4885MAP3K20 925/4885PIK3C3 3074/4885
US-20110098275-A1 5-ALKYNYL-PYRIDINES MKI67, KIT, CCNA1 BRAF 357/4885MAP3K20 540/4885PIK3C3 4308/4885
US-11945799-B2 4-ethynylpyridine derivatives useful as GCN2 inhibitors EIF2AK4, GCN1, EIF5B BRAF 2826/4885MAP3K20 1276/4885PIK3C3 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.